FindTrial
Sign In

Study of two anti-allergic drugs in allergic Conjunctivitis

A Prospective, Randomized, Open Label, Parallel Group, Comparative Study Of The Efficacy And Tolerability Of Bepotastine Besilate And Olopatadine Hydrochloride Eyedrops In Allergic Conjunctivitis In A Tertiary Care Hospital

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/05/013792
Enrollment
60
Registered
2018-05-09
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Allergic Conjunctivitis

Interventions

None listed

Sponsors

kempegowda institute of medical sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: a. Subjects aged >=18 years with clinical diagnosis of seasonal allergic conjunctivitis and perennial allergic conjunctivitis. b. Willingness to give written informed consent and be available for regular follow-up visits.

Exclusion criteria

Exclusion criteria: a. Bacterial, viral or fungal conjunctivitis. b. Subjects who have used topical or oral corticosteroids in the past two weeks. c. Severe allergic conjunctivitis including vernal keratoconjunctivitis, atopic keratoconjunctivitis and giant papillary conjunctivitis. d. History of severe dry eye. e. History of ocular herpes. f. Pregnant or lactating women. g. Known hypersensitivity to the study drugs. h. Subjects already taking the study drugs.

Design outcomes

Primary

MeasureTime frame
Comparative Study Of The Efficacy And Tolerability Of Bepotastine Besilate And Olopatadine Hydrochloride Eyedrops In Allergic Conjunctivitis In A Tertiary Care HospitalTimepoint: one and half year—

Secondary

MeasureTime frame
Comparative Study Of The Efficacy And Tolerability Of Bepotastine Besilate And Olopatadine Hydrochloride Eyedrops In Allergic Conjunctivitis In A Tertiary Care HospitalTimepoint: one and half year—

Countries

India

Contacts

Public ContactDr Sudipto Chatterjee

Kempegowda institute of medical sciences

vijendra_ramaiah@yahoo.co.in8217097546

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026